SCHEMBL2999856

SCHEMBL2999856

c1ccc(COc2ccnc3[nH]ccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 2/20 0.51
CSF1R P07333 2/20 0.51
IKBKB O14920 1/20 0.51
CHUK O15111 1/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
PAK4 O96013 1/20 0.51
RET P07949 1/20 0.51
IGF1R P08069 1/20 0.51
FGFR1 P11362 1/20 0.51
PRKACA P17612 1/20 0.51
FLT1 P17948 1/20 0.51
LTK P29376 1/20 0.51
GRK5 P34947 1/20 0.51
KDR P35968 1/20 0.51
MAP2K2 P36507 1/20 0.51
MAPK8 P45983 1/20 0.51
CSNK1A1 P48729 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365456 0.86 AURKB (0.56) AURKBCSF1RIKBKBCHUKDAPK3
SCHEMBL29244612 0.85 PRKCI (0.42) AURKBCSF1RIKBKBCHUKDAPK3
SCHEMBL10125078 0.84 AURKB (0.56) AURKBCSF1RIKBKBCHUKDAPK3
SCHEMBL29244608 0.83 RXRA (0.50) IKBKBCHUKMAPTNUDT1POLB
SCHEMBL5322848 0.78 LMNA (0.52) CSF1RFGFR1L3MBTL1
SCHEMBL2992617 0.77 NUDT1 (0.55) AURKBCSF1RIKBKBCHUKDAPK3
SCHEMBL5328761 0.76 AURKB (0.39) AURKBCSF1RIKBKBCHUKDAPK3
SCHEMBL5138865 0.75 LMNA (0.44) ELANEL3MBTL1ALDH1A1POLB
SCHEMBL6250294 0.75 KDR (0.51) AURKBCSF1RIKBKBCHUKDAPK3
SCHEMBL6431905 0.75 LTA4H (0.44) DYRK1AEGFRCDC7DBF4LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199543-A1 Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2024-06-20 US disclosed
US-11952342-B2 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-04-09 US disclosed
US-20240101513-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2024-03-28 US disclosed
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-03-26 US disclosed
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-03-26 US disclosed
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-03-26 US disclosed
US-20230348380-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2023-11-02 US disclosed
US-20230348380-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2023-11-02 US disclosed
US-20230348380-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2023-11-02 US disclosed
EP-2125803-B1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NAT RECH SCIENT (FR) 2013-04-10 EP disclosed
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101513-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 AURKB 315/4885CSF1R 4443/4885IKBKB 999/4885
US-20230348380-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 AURKB 315/4885CSF1R 4443/4885IKBKB 999/4885
US-11952342-B2 Aza-substituted psilocin analogs and methods of synthesizing the same TOP2A, PAICS, TOP1 AURKB 455/4885CSF1R 4576/4885IKBKB 1020/4885
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF BAD, PPOX, CASP3 AURKB 304/4885CSF1R 3556/4885IKBKB 1393/4885
US-20240199543-A1 Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 AURKB 455/4885CSF1R 4576/4885IKBKB 1020/4885
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same TOP2A, PAICS, TOP1 AURKB 455/4885CSF1R 4576/4885IKBKB 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.